



## **Launch of the cobas® 5800 System: Accessible innovation to enable multi-disease testing**

ASLM2021 Satellite Session

### **Sponsor**

Roche Diagnostics

### **Date and Time**

17 November 2021, 7AM-8AM GMT

### **Summary**

Every three seconds a person dies from infectious diseases, making this the second leading cause of deaths worldwide. The emergence of new infectious diseases has further challenged health systems across Africa. In particular, the Covid pandemic has highlighted the need for countries to adopt innovative diagnostics solutions in addition to increasing their testing capacities.

For several years, Roche Diagnostics multi-pathogen and high throughput fully automated testing solutions - cobas® 4800/ 6800/8800 Systems - have greatly contributed to the fight against HIV and other infectious diseases.

Today, Roche has expanded its focus by responding to the needs of lower volume laboratories and seeking to bring diagnostics closer to the patient by launching the new fully automated molecular platform, the cobas® 5800 System. It complements, thus, the cobas® Roche molecular testing solutions, which now meets all laboratory needs.

During this symposium, you will discover how the new cobas® 5800 System allows you to: easily and rapidly implement your molecular diagnostics solution; consolidate your routine testing on a compact instrument; and get every test available at any time, through a flexible reagent concept. Additionally, you will find out how the multi-testing approach offered by Roche, combined with new, innovative offerings provides laboratories and patients an optimised, end-to-end solution.

### **Learning Objectives**

- To present the new cobas® 5800 System that will offer more options to programmes (across disease areas) and laboratories across the SSA region
- To demonstrate functionality that will support further optimisation and help drive multi-Disease testing on a single instrument/platform
- To highlight how the system will help meet needs across the region including multi-testing and providing an option for low-volume settings

### **Target Audience**

Laboratory professionals, Technical Working Group members, all Programmes Managers (HIV, MTB, HPV HCV etc.), Implementing partners, scientists, funders